Table 2 Treatment and acute complications during chemoradiotherapy
Treatment N (%) | Low dose 97 (12.4%) | Intermediate dose 411 (52.8%) | High dose 271 (34.8%) | P value |
|---|---|---|---|---|
Chemotherapy during CRT | ||||
Mean cumulative dose of cisplatin during CRT (mg/m2) (±SD) | 103.62 ± 27.94 | 206.9 ± 23.99 | 286.54 ± 16.03 | < 0.001 |
CRT regimen | ||||
Q1 week | 11 (11.3%) | 26 (6.3%) | 32 (11.8%) | 0.031 |
Q3 week | 86 (88.7%) | 385 (93.7%) | 239 (88.2%) | |
Completed planned cycle during CRT | 1 (1%) | 154 (37.5%) | 267 (98.5%) | < 0.001 |
Median number of actual given cycles during CRT (range) | ||||
Weekly | 3 (1, 3) | 6 (5, 6) | 7 (7, 7) | < 0.001 |
Q3 week | 1 (1, 2) | 2 (2, 3) | 3 (3, 3) | < 0.001 |
Adjuvant chemotherapy regimen | ||||
Cisplatin-5FU | 36 (37.1%) | 345 (83.9%) | 230 (84.9%) | < 0.001 |
Carboplatin-5FU | 24 (24.7%) | 18 (4.4%) | 22 (8.1%) | |
No adjuvant chemotherapy | 37 (38.1%) | 48 (11.7%) | 19 (7%) | |
Number of completed cycle of adjuvant chemotherapy | ||||
1 cycle | 7 (11.9%) | 38 (10.3%) | 25 (10.2%) | < 0.001 |
2 cycles | 10 (16.9%) | 57 (15.4%) | 83 (33.7%) | |
3 cycles | 42 (71.2%) | 274 (74.3%) | 138 (56.1%) | |
Mean cumulative dose of adjuvant cisplatin (mg/m2) (±SD) | 199.24 ± 93.3 | 203.67 ± 63.45 | 184.08 ± 64.24 | 0.002 |
Radiotherapy (RT) | ||||
Technique | ||||
IMRT | 61 (62.9%) | 298 (72.5%) | 134 (49.4%) | < 0.001 |
3D | 16 (16.5%) | 51 (12.4%) | 55 (20.3%) | |
2D | 19 (19.6%) | 53 (12.9%) | 77 (28.4%) | |
Unknown | 1 (1%) | 9 (2.2%) | 5 (1.8%) | |
Mean actual dose (cGy) (±SD) | 6563.75 ± 1399.55 | 6974.26 ± 346.24 | 6989.42 ± 181.96 | < 0.001 |
Median duration (weeks) (range) | 7.07 (6.57,8.14) | 7.14 (6.71,7.86) | 7.29 (7.0,8.0) | 0.013 |
RT delay (> 7 days) | 28 (29.2%) | 67 (16.7%) | 62 (23.4%) | 0.010 |
Acute complication during CRT | ||||
Cisplatin Interruption | 64 (66%) | 186 (45.3%) | 111 (41%) | < 0.001 |
Cisplatin Delay | 35 (36.1%) | 75 (18.2%) | 43 (15.9%) | < 0.001 |
Hospitalization | 11 (11.5%) | 15 (3.7%) | 30 (11.1%) | < 0.001 |
Termination of cisplatin | 66 (68%) | 81 (19.7%) | 13 (4.8%) | < 0.001 |
- Switch to carboplatin | 31 (45.5%) | 8 (9.9%) | 0 (0%) | < 0.001 |
At least 1 acute complication | 77 (79.4%) | 191 (46.5%) | 123 (45.4%) | < 0.001 |
Cisplatin-related toxicity during CRT | ||||
All cisplatin-related toxicity | 49 (50.5%) | 144 (35%) | 113 (41.7%) | 0.012 |
Mean percent dropped of CCr after CRT completion (±SD) | −8.79 ± 40.09 | −18.23 ± 26.6 | −24.03 ± 24.68 | 0.001 |
AKI | 15 (15.5%) | 25 (6.1%) | 14 (5.2%) | 0.002 |
AKD | 27 (39.1%) | 98 (28.7%) | 81 (38.2%) | 0.038 |
Hospitalization due to cisplatin | 10 (10.3%) | 10 (2.4%) | 23 (8.5%) | < 0.001 |
Treatment interruption due to cisplatin | 36 (37.1%) | 71 (17.3%) | 41 (15.1%) | < 0.001 |